Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PROSPECTIVE, PHASE 3, OPEN-LABEL, INTERNATIONAL MULTICENTER STUDY ON EFFICACY AND SAFETY OF PROPHYLAXIS WITH rVWF IN SEVERE VON WILLEBRAND DISEASE

NCT02973087 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT02973087
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02973087 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PROSPECTIVE, PHASE 3, OPEN-LABEL, INTERNATIONAL MULTICENTER STUDY ON EFFICACY AND SAFETY OF PROPHYLAXIS WITH rVWF IN SEVERE VON WILLEBRAND DISEASE
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
November 16, 2017
Completion date
July 6, 2020
Enrollment
29 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

von willebrand disease